comprehensive -WSS

comprehensive

author：comprehensive 2025-08-12 09:12:51 - browse：76516

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Gilead might be held responsible for not developing a drug

knowledge

Wikipedia

WSS

The strategy behind pharma's lawsuits over drug pricing reform

Death of patient in Alzheimer’s trial raises question of possible risks

Biden report: The neurospychology of memory and aging

Senators start work on Medicare physician payment reform

#NeedHerScience: shining a light on gender disparities in medicine

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Wikipedia

In Memoriam: Notable people who died in 2023

Readout LOUD podcast: How biotech is using artificial intelligence

The high cost of giving birth even with insurance

3 hurdles to bringing medical devices to the U.S. market

Continuity nursing helped my family in our darkest PICU moments

What we’ve learned from the Aduhelm mess

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC concerned about possible undetected monkeypox spread in U.K.

Supreme Court strikes down use of affirmative action

BioAge raises $170M for combination therapy with Zepbound

knowledge

Ask STAT: What do you want to know about ChatGPT in medicine?

Industry veterans launch new biotech VC with $310M

Why drug prescriptions should include diagnoses

Donald Trump's relentless attacks on special counsel Jack Smith

The story of mRNA: From a loose idea to a tool that may help curb Covid

What should King Charles tell the public about his cancer?

entertainment

knowledge

Wikipedia

knowledge